Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study (Q91077536)
Jump to navigation
Jump to search
scientific article published on 01 November 2019
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study |
scientific article published on 01 November 2019 |
Statements
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study (English)
Barbara Burtness
Kevin J Harrington
Richard Greil
Denis Soulières
Makoto Tahara
Gilberto de Castro
Amanda Psyrri
Neus Basté
Prakash Neupane
Åse Bratland
Thorsten Fuereder
Brett G M Hughes
Ricard Mesía
Nuttapong Ngamphaiboon
Tamara Rordorf
Wan Zamaniah Wan Ishak
Ruey-Long Hong
René González Mendoza
Ananya Roy
Yayan Zhang
Burak Gumuscu
Jonathan D Cheng
Fan Jin
KEYNOTE-048 Investigators